N81 Long-term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with residual teratoma

Argirovic, D.; Argirović, A.; Stanic, Vojkan

doi:10.1016/s1569-9056(09)74855-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following induction chemotherapy approximately 40% of patients undergoing RPLA will have teratoma in the retroperitoneum, and an additional 10% to 15% will have viable cancer 5,6 . Teratoma is chemorefractory, and has an unpredictable biological potential with the possibility of growth, invasion of adjacent organs, and devastating late relapse if not completely resected [7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

Can we predict the presence of teratoma in the retroperitoneum before post-chemotherapy retroperitoneal lymphadenectomy?

Argirović¹,

Argirović²

2015

Mat Med

View full text Add to dashboard Cite

The biological potential of teratoma remains unpredictable, therefore identifying its presence in the retroperitoneum remains important. We evaluated patients undergoing post-chemothe rapy retroperitoneal lymphadenectomy (PC-RPLA) for nonseminomatous testicular tumors (NSTT), to determine predictors of teratomatous elements in the retroperitoneum. We identified 161 patients from 1982 to 2005 who underwent PC-RPLA for metastatic NSTT. Multiple clinical and pathological variables were reviewed from out RPLA database. Of the 161 patients in our series, 112 (70%) received only induction chemotherapy and 49 (30%) required 2nd line chemotherapy. Studies of retroperitoneal pathology demonstrated the presence of fibrosis in 44 (27%), teratoma in 82 (51%) and vital carcinoma in 35(22%).Among 82 patients (51%) with finding of teratomatous elements at PC-RPLA, we revealed the presence ofmature teratoma in 85%, immature teratoma in 12% and teratoma with malignant transformation in 3%. Of the 99 patients (61%) with teratomatous elements in the primary NSTT, 61 (62%) had teratoma at PC-RPLA. Even in the absence of teratoma in the primary NSTT, teratoma was present in the retroperitoneum in 21 of 62 patients (32%)(p<0.0001). All patients had normal values of serum tumor markers (STM) at PC-RPLA. Post-chemotherapy retroperitoneal residual mass measuring <2 cm, from 2.1-5.0 cm and > 5 cm in diameter occured in 30%, 52% and 55%, respectively. By multivariate analysis , teratoma in the orchiectomy specimen (p<0.005), relative change in nodal size before and after chemotherapy (p<0.005), and no requirement for 2nd line chemotherapy (p=0.33) were independent predictors for the presence of the teratoma in the retroperitoneum. Teratoma remains

show abstract